3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Sarcoma
1
Other hematologic neoplasm
1
Dermatologic
1
Conditions
Melanoma
1
Interventions
pembrolizumab
65
Nivolumab
58
Ipilimumab
32
Cyclophosphamide
22
Specimen Handling
16
Magnetic Resonance Spectroscopy
15
Biopsy
15
relatlimab
13
cemiplimab
13
fludarabine
12
Opdualag
12
binimetinib
10
Blood Specimen Collection
10
aldesleukin
9
Radiosurgery
9
encorafenib
8
Interleukin-2
8
atezolizumab
7
Immunotherapy
7
tebentafusp
6
mogamulizumab
6
fludarabine phosphate
6
Temozolomide
6
Surgical Procedures, Operative
6
Paclitaxel
6
Immunoglobulin G
6
CTLA-4 Antigen
6
Radiotherapy
5
Disulfides
5
Bevacizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Adjuvants, Immunologic
×
Dermatologic
×
Clear all
NCT04594187
2026-02-17
MelPORT
M.D. Anderson Cancer Center
Phase 2
Recruiting
168 enrolled